MX2015008889A - Method for treating cancer based on mutation status of k-ras. - Google Patents
Method for treating cancer based on mutation status of k-ras.Info
- Publication number
- MX2015008889A MX2015008889A MX2015008889A MX2015008889A MX2015008889A MX 2015008889 A MX2015008889 A MX 2015008889A MX 2015008889 A MX2015008889 A MX 2015008889A MX 2015008889 A MX2015008889 A MX 2015008889A MX 2015008889 A MX2015008889 A MX 2015008889A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- ras
- mutation status
- cancer based
- status
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides methods and compositions for treating cancer by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and/or b) a therapeutic agent (e.g., gemcitabine) based upon K-ras mutation status.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361848793P | 2013-01-11 | 2013-01-11 | |
US201361752417P | 2013-01-14 | 2013-01-14 | |
US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008889A true MX2015008889A (en) | 2015-11-13 |
Family
ID=51165319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008889A MX2015008889A (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140199405A1 (en) |
EP (1) | EP2943184A4 (en) |
JP (1) | JP2016506908A (en) |
KR (1) | KR20150103746A (en) |
AU (1) | AU2014205254A1 (en) |
BR (1) | BR112015016466A2 (en) |
CA (1) | CA2897581A1 (en) |
HK (1) | HK1217292A1 (en) |
IL (1) | IL239740A0 (en) |
MX (1) | MX2015008889A (en) |
WO (1) | WO2014110408A1 (en) |
ZA (1) | ZA201504878B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1585548T1 (en) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CN105288630A (en) | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | Combinations and modes of administration of therapeutic agents and combination therapy |
RU2451510C2 (en) | 2005-08-31 | 2012-05-27 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Composition and method for production of enhanced stability medications slightly soluble in water |
WO2008021288A2 (en) | 2006-08-11 | 2008-02-21 | Johns Hopkins University | Consensus coding sequences of human breast and colorectal cancers |
PT2117520T (en) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
CA2689914C (en) * | 2007-06-01 | 2016-08-16 | Abraxis Bioscience, Llc | Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers |
BRPI1012525A2 (en) | 2009-04-15 | 2018-07-10 | Abraxis Bioscience, Llc. | prion-free nanopaticle compositions and methods for their manufacture |
CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
KR20130028727A (en) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
SG10201906075VA (en) | 2010-03-29 | 2019-08-27 | Abraxis Bioscience Llc | Methods of treating cancer |
SG186112A1 (en) | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
BR112013027674A2 (en) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "uses of nanoparticle compositions, compositions comprising said nanoparticles and single needle catheter". |
DK2790675T3 (en) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | APPLICATION OF POLYMER EXCIPIENTS FOR FREEZING DRY OR FREEZING OF PARTICLES |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP2968254B1 (en) | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
US9962373B2 (en) | 2013-03-14 | 2018-05-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
US9757439B2 (en) | 2014-05-06 | 2017-09-12 | Targovax Asa | Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
SG10202107198SA (en) | 2015-06-29 | 2021-08-30 | Abraxis Bioscience Llc | Methods of treating epithelioid cell tumors |
MX2019003694A (en) * | 2016-10-07 | 2019-06-24 | Abraxis Bioscience Llc | Methods of treating biliary tract cancer. |
EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
WO2021226403A1 (en) * | 2020-05-08 | 2021-11-11 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105288630A (en) * | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | Combinations and modes of administration of therapeutic agents and combination therapy |
ES2398709T5 (en) * | 2005-06-28 | 2017-04-18 | Genentech, Inc. | Mutations in EGFR and KRAS to predict a patient's response to treatment with EGFR inhibitors |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
WO2008112269A2 (en) * | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras mutations and anti-egfr antibody therapy |
WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
RU2561055C2 (en) * | 2009-08-25 | 2015-08-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Combined therapy with compositions of taxane nanoparticles and hedgehog inhibitors |
SG10201906075VA (en) * | 2010-03-29 | 2019-08-27 | Abraxis Bioscience Llc | Methods of treating cancer |
JP2013526852A (en) * | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Circulating biomarkers for disease |
WO2011146803A1 (en) * | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with hsp90 inhibitory compounds |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
WO2012166899A2 (en) * | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
CA2865335A1 (en) * | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en active Application Filing
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/en not_active Application Discontinuation
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/en not_active Application Discontinuation
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/en unknown
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/en active Pending
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
-
2016
- 2016-05-09 HK HK16105270.2A patent/HK1217292A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2943184A4 (en) | 2016-07-20 |
HK1217292A1 (en) | 2017-01-06 |
BR112015016466A2 (en) | 2017-07-11 |
WO2014110408A1 (en) | 2014-07-17 |
US20140199405A1 (en) | 2014-07-17 |
EP2943184A1 (en) | 2015-11-18 |
KR20150103746A (en) | 2015-09-11 |
ZA201504878B (en) | 2016-10-26 |
IL239740A0 (en) | 2015-08-31 |
JP2016506908A (en) | 2016-03-07 |
CA2897581A1 (en) | 2014-07-17 |
AU2014205254A1 (en) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008889A (en) | Method for treating cancer based on mutation status of k-ras. | |
MX2015008888A (en) | Method for treating cancer based on level of a nucleoside transporter. | |
MX2015011753A (en) | Methods of treating bladder cancer. | |
MX2021002455A (en) | Methods of treating epithelioid cell tumors. | |
IL291932B1 (en) | Nanoparticle compositions for sustained therapy | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX370662B (en) | Methods of treating lung cancer. | |
MX2017016491A (en) | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy. | |
BR112018013065A2 (en) | compositions and methods for the treatment of hemoglobinopathies | |
MX2015011783A (en) | Methods of treatment of pediatric solid tumor. | |
MX2018006240A (en) | Compositions comprising bacterial strains. | |
MX2016002544A (en) | Compounds useful as immunomodulators. | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
MX2020009223A (en) | Afucosylated anti-fgfr2iiib antibodies. | |
MX364637B (en) | Methods of treating cancer. | |
MX2017016519A (en) | Biomarkers for nanoparticle compositions. | |
MX356368B (en) | Prodrugs of fumarates and their use in treating various deseases. | |
WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
MX2015011606A (en) | Methods of treating cancer and preventing cancer drug resistance. | |
MX2018000715A (en) | Methods for treating cancer using apilimod. | |
MX2015010829A (en) | Therapeutic compounds and uses thereof. | |
MX2016009590A (en) | Apilimod compositions and methods for using same. | |
PH12017501879A1 (en) | Methods for treating cancer | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer |